What's Next For Regeneron After A Therapy Trial Failure?
November 28, 2017 at 13:30 PM EST
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) announced results Monday from two mid-stage studies for diabetic macular edema and ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.